Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia

Psychosomatics

Volumn 57, Issue 2, 2016, Pages 208-216

  Degenhardt, Elisabeth K ^a   Witte, Michael M ^b   Case, Michael G ^c   Yu, Peng ^c   Henley, David B ^b,d   Hochstetler, Helen M ^b   D'Souza, Deborah N ^e   Trzepacz, Paula T ^d  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b Neuroscience Department LLC Lilly USA   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; FLORBETAPIR F 18; GALANTAMINE; MEMANTINE; RIVASTIGMINE; SOLANEZUMAB; TACRINE; AMYLOID; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; BRAIN; DIAGNOSTIC IMAGING; METABOLISM; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; AUTOPSY; BRAIN; ETHYLENE GLYCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84959869782     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2015.12.002     Document Type: Article

References (38)

1. Rasmusson D.X., Brandt J., Steele C., Hedreen J.C., Troncoso J.C., Folstein M.F. Accuracy of clinical diagnosis of Alzheimer's disease and clinical features of patients with non-Alzheimer's disease neuropathology. Alzheimer Dis Assoc Disord 1996, 10(4):180-188.
2. Pearl G.S. Diagnosis of Alzheimer's disease in a community hospital-based brain bank program. South Med J 1997, 90(7):720-722.
3. Nagy Z., Esiri M.M., Hindley N.J., et al. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Disord 1998, 9(4):219-226.
4. Petrovitch H., White L.R., Ross G.W., et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 2001, 57(2):226-234.
5. Mastwyk M., Ames D., Ellis K.A., Chiu E., Dow B. Disclosing a dementia diagnosis: what do patients and family consider important?. Int Psychogeriatr 2014, 26(8):1263-1272.
6. Hsiung G.R. Epidemiology of Alzheimer's disease and dementia. Atlas of Alzheimer's Disease 2007, Informa UK Ltd, London. H.H. Feldman (Ed.).
7. Speechly C.M., Bridges-Webb C., Passmore E. The pathway to dementia diagnosis. Med J Aust 2008, 189(9):487-489.
8. Bradford A., Kunik M.E., Schulz P., Williams S.P., Singh H. Missed and delayed diagnosis of dementia in primary care: Prevalence and contributing factors. Alzheimer Dis Assoc Disord 2009, 23:306-314.
9. Leung K.K., Finlay J., Silvius J.L., et al. Pathways to diagnosis: exploring the experiences of problem recognition and obtaining a dementia diagnosis among Anglo-Canadians. Health Soc Care Community 2011, 19(4):372-381.
10. Villemagne V.L., Burnham S., Bourgeat P., et al. Australian Imaging Biomarkers and Lifestyle (AIBL) research group (2013). Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367.
11. Jack C.R., Knopman D.S., Jagust W.J., et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
12. Geldmacher D.S., Kirson N.Y., Birnbaum H.G., Eapen S., Kantor E., Cummings A.K., Joish V.N. Implications of early treatment among Medicaid patients with Alzheimer's disease. Alzheimers Dement 2014, 10:214-224.
13. Johnson K.A., Minoshima S., Bohnen N.I., et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013, 9:e-1-16.
14. Genius J., Klafki H., Benninghoff J., Essellman H., Wiltfang J. Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci 2012, 262(2 Suppl):S71-S77.
15. Beach T.G., Monsell S.E., Phillips L.E., Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012, 71:266-273.
16. Hogervorst E., Barnetson L., Jobst K.A., et al. Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. Dement Geriatr Cogn Disord 2000, 11:107-113.
17. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
18. Cacabelos R. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics 2004, 5:1049-1105.
19. Clark C.M., Schneider J.A., Bedell B.J., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. J Am Med Assoc 2011, 305:275-283.
20. Joshi A.D., Pontecorvo M.J., Clark C.M., et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012, 53:378-384.
21. Clark C.M., Pontecorvo M.J., Beach T.G., et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012, 11:669-678.
22. Doody R.S., Thomas R.G., Farlow M., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:311-321.
23. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
24. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141:1356-1364.
25. Mohs R.C., Knopman D., Petersen R.C., et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 1997, 11(2 Suppl):S13-S21.
26. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(2 Suppl):S33-S39.
27. NACC Clinical Dementia Rating. ; 2006. Accessed January 9, 2014. http://www.alz.washington.edu/NONMEMBER/UDS/DOCS/VER1_2/guide.pdf.
28. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
29. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
30. Trzepacz P.T., Saykin A., Yu P., et al. Alzheimer's Disease Neuroimaging Initiative. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. Am J Geriatr Psychiatry 2013, 21:607-622.
31. Sheikh J.I., Yesavage J.A. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986, 5:165-173.
32. Witte M., Trzepacz P., Case M., et al. Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2014, 26(3):214-220.
33. Sperling R, Salloway S, Raskind M, et al: Bapineuzumab Phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoprotein E e4 carriers (Study 302) and non-carriers (Study 301). Electronic resource. Accessed February 11, 2013. http://www.ctad.fr/07-download/Congres2012/PressRelease/Final-Sperling-CTAD-Presentation-10-29-12.pdf.
34. Chiao P., Suhy J., Barakos J., et al. P18 - Amyloid PET screening results by APOE E4 status from a phase 1B clinical study 221AD103 in prodromal to mild AD patients. J Nutr Health Aging 2013, 17:824.
35. Salloway S., Sperling R., Fox N.C., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
36. Green R.C., Roberts J.S., Cupples L.A., et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009, 361:245-254.
37. Roberts J.S., Christensen K.D., Green R.C. Using Alzheimer's disease as a model for genetic risk disclosure: Implications for personal genomics. Clin Genet 2011, 80:407-414.
38. Fleisher A.S., Chen K., Liu X., et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011, 68:1404-1411.